pharma industry

Should Life Sciences Manufacturers Care about FQHCs?

By Amber Glende – If you work in life sciences, whether in pharma, diagnostics, or vaccines, Federally Qualified Health Centers might not be on your radar. Many manufacturers focus their commercial strategies on large health systems, private practices, and specialty networks, leaving FQHCs largely untapped.


Biosimilars, Saving Costs on Specialty Drugs

By Tom Dorsett – As of April 2023, the FDA has approved the use of 40 “biosimilars”, which are a less expensive version of an advanced “biologic” medication. The rise of biosimilars is a major source of excitement as a way to control rising drug costs. But is the fervor warranted?